Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics

(2022) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies

(2022) Massimo Filippi et al.   JAMA Neurology

A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine

(2022) Hui Jing Yu et al.   MOVEMENT DISORDERS

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review

(2021) Danko Jeremic et al.   AGEING RESEARCH REVIEWS

Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform

(2021) James C. Robinson   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

(2021) Stephen Salloway et al.   JAMA Neurology

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

The impact of mobility limitations on health outcomes among older adults

(2018) Shirley Musich et al.   GERIATRIC NURSING

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

(2018) Joseph W. Arndt et al.   Scientific Reports

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

(2018) Stina Tucker et al.   JOURNAL OF ALZHEIMERS DISEASE

APOE genotype and Alzheimer’s immunotherapy

(2017) Joanna E. Pankiewicz et al.   Oncotarget

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

(2008) Michael Pride et al.   Neurodegenerative Diseases